Friday 6 November 2026
Export AMPH’s income statement to Excel — free account
Amphastar Pharmaceuticals, Inc.
AMPH Healthcare Drug Manufacturers Specialty & Generic
Amphastar Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.9 million, down 1.65% from fiscal 2024.
- Revenue
- +8.22%
- EPS
- +134.2%
- Free cash flow
- −29.4%
- Total debt
- +0.57%
Quarter to September 2026, against a year earlier
27.59
0.43
−1.53%
Follow AMPH
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
6 | 6 | 5 | 6 |
| 12.90% | 10.39% | 10.30% | 12.44% | ||
| 6.12% | 4.84% | 4.68% | 5.86% | ||
ROIC |
7.88% | 6.69% | 6.57% | 6.12% | |
Return on Tangible Assets |
12.44% | 10.20% | 11.49% | 13.48% | |
Average Days of Receivables |
81.49 | 79.76 | 73.74 | 0.00 | |
Free Cash Flow per Share |
2.54 | 2.98 | 3.50 | 3.26 | |
Free Cash Flow |
118.83 | 135.19 | 152.89 | 139.02 | |
Capital Expenditures |
(37.28) | (33.69) | (31.72) | (36.31) | |
| Other line items | |||||
Cash ROIC |
7.05% | 8.05% | 9.14% | 9.74% | |
Accounts Receivable Turnover |
4.82 | 4.76 | 5.18 | 0.00 | |
Accounts Payable Turnover |
2.38 | 2.31 | 1.83 | 2.21 | |
Inventory Turnover |
2.20 | 2.13 | 2.06 | 2.20 | |
Average Days of Payables |
148.83 | 146.89 | 240.24 | 154.64 | |
Days of Inventory on Hand |
177.46 | 163.73 | 171.94 | 160.02 | |
Tax Rate |
(0.21) | (0.23) | (0.23) | (0.24) | |
Research and Development Expense of Revenue |
11.92% | 12.84% | 12.95% | 12.38% | |
Selling, General and Administrative Expense of Revenue |
18.03% | 18.31% | 19.08% | 15.70% | |
Share Based Compensation of Revenue |
3.79% | 3.91% | 3.95% | 3.97% | |
Interest Coverage |
5.51 | 4.53 | 4.37 | 5.25 | |
Operating CF/Net income |
1.59 | 2.13 | 2.35 | 1.77 | |
Depreciation/Fixed assets |
0.19 | 0.20 | 0.19 | 0.00 | |
Capex/Depreciation |
(0.62) | (0.55) | (0.52) | 0.00 | |
Revenue per Share |
15.40 | 15.90 | 16.73 | 17.52 | |
Operating CF per Share |
3.34 | 3.73 | 4.23 | 4.12 | |
Capex per Share |
(0.80) | (0.74) | (0.73) | (0.85) | |
Capex to Sales |
0.05 | 0.05 | 0.04 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026